Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis (SUPERNEXT)
Sponsor: Amsterdam UMC, location VUmc
A PHASE4 clinical study on Relapsing Remitting Multiple Sclerosis, this trial is ongoing. The trial is conducted by Amsterdam UMC, location VUmc and has accumulated 10 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE4
-
May 2025 — Sep 2025 [monthly]
Unknown PHASE4
Status: Enrolling By Invitation → Unknown
-
Sep 2024 — May 2025 [monthly]
Enrolling By Invitation PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Enrolling By Invitation PHASE4
-
May 2023 — Jul 2024 [monthly]
Enrolling By Invitation PHASE4
Status: Recruiting → Enrolling By Invitation
▶ Show 5 earlier versions
-
May 2022 — May 2023 [monthly]
Recruiting PHASE4
-
Oct 2021 — May 2022 [monthly]
Recruiting PHASE4
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE4
-
Jun 2020 — Jan 2021 [monthly]
Recruiting PHASE4
-
Feb 2020 — Jun 2020 [monthly]
Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Amsterdam UMC, location VUmc
- Innovatiefonds Zorgverzekeraars
- Stichting MS Research
- Stichting Treatmeds
For direct contact, visit the study record on ClinicalTrials.gov .